Thank you for considering the The Assessment of Prednisone in Remission (TAPIR) Trial.
Your patient has recently approached you about their participation in this trial.
This trial is being conducted by Peter Merkel, MD, director of the Vasculitis Clinical Research Consortium; and funded under the National Heart Lung and Blood Institute.
You do not need IRB approval.
The US Government Office for Human Research Protections (OHRP) and the University of South Florida IRB agree that as this patient's treating physician, you are not engaged in research for this trial design. All patients will be consented electronically by the University of South Florida. (USF IRB# Pro00013241)
Your patient remains under your care.
You, as this patient's treating physician, may modify their prednisone dose as clinically indicated during the trial.
This trial will evaluate if clinical research can be conducted in a community setting.
If you have any questions please contact the trial coordinator at TAPIR@epi.usf.edu or 1-888-443-1793
For your convenience, we have included a PowerPoint slide presentation of TAPIR trial facts and information.
*other conditions may apply. Learn more